doi: 10.3389/fcvm.2025.1535134 Received 26 November 2024 Accepted 28 March 2025 Published 24 April 2025 Volume 12 - 2025 Edited by Preetha Shridas, University of Kentucky, United States Reviewed by Aneesh Dhore-patil, Houston Methodist Hospital, United States Raffaele Carraro, La Princesa University Hospital, Spain Updates Copyright 2025 Turkistani
After 8 weeks, the rats showed manifestations such as dull hair and irritability, an increased liver index, diffuse fatty hepatocytes, varying degrees of macrovesicular and microvesicular steatosis and occasionally inflammatory cell infiltration
Originally developed to treat type 2 diabetes, semaglutide is now FDA-approved for weight management and has shown impressive results in clinical trials
Nat Rev Endocrinol (2011) 8:22836
long-term safety in humans is not established